BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 352 filers reported holding BIO-TECHNE CORP in Q1 2019. The put-call ratio across all filers is 1.52 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2019 | $11,245,000 | +42.3% | 56,634 | +3.8% | 0.01% | +27.3% |
Q4 2018 | $7,900,000 | -67.7% | 54,586 | -54.5% | 0.01% | -26.7% |
Q3 2018 | $24,492,000 | +176.3% | 119,996 | +100.3% | 0.02% | +36.4% |
Q2 2018 | $8,863,000 | +3.0% | 59,908 | +5.1% | 0.01% | 0.0% |
Q1 2018 | $8,607,000 | +37.9% | 56,983 | +18.2% | 0.01% | +37.5% |
Q4 2017 | $6,243,000 | +23.6% | 48,189 | +15.3% | 0.01% | +14.3% |
Q3 2017 | $5,051,000 | -28.7% | 41,782 | -30.7% | 0.01% | -30.0% |
Q2 2017 | $7,086,000 | +18.7% | 60,303 | +2.7% | 0.01% | +11.1% |
Q1 2017 | $5,971,000 | +11.7% | 58,744 | +13.0% | 0.01% | +12.5% |
Q4 2016 | $5,347,000 | +32.7% | 52,001 | +41.4% | 0.01% | +14.3% |
Q3 2016 | $4,028,000 | +10.5% | 36,785 | +13.8% | 0.01% | +16.7% |
Q2 2016 | $3,646,000 | +0.7% | 32,327 | -15.6% | 0.01% | -14.3% |
Q1 2016 | $3,619,000 | +10.3% | 38,291 | +5.0% | 0.01% | +16.7% |
Q4 2015 | $3,282,000 | -0.2% | 36,472 | +2.5% | 0.01% | -14.3% |
Q3 2015 | $3,289,000 | +16.4% | 35,575 | +24.0% | 0.01% | +40.0% |
Q2 2015 | $2,825,000 | -5.0% | 28,693 | -3.2% | 0.01% | -16.7% |
Q1 2015 | $2,974,000 | +9.8% | 29,655 | +1.1% | 0.01% | +20.0% |
Q4 2014 | $2,709,000 | – | 29,319 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
Westwind Capital | 27,946 | $9,687,000 | 3.17% |
MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |